Cardiovascular Risk Prediction in Patients With Stable and Unstable Coronary Heart DiseaseMORROW, David A.Circulation (New York, N.Y.). 2010, Vol 121, Num 24, pp 2681-2691, issn 0009-7322, 11 p.Article

[Impact of Biomarkers, Proteomics, and Genomics in Cardiovascular Disease]APPLE, Fred S; BLANKENBERG, Stefan; MORROW, David A et al.Clinical chemistry (Baltimore, Md.). 2012, Vol 58, Num 1, issn 0009-9147, 305 p.Serial Issue

Troponins in acute coronary syndromesSCIRICA, Benjamin M; MORROW, David A.Progress in cardiovascular diseases. 2004, Vol 47, Num 3, pp 177-188, issn 0033-0620, 12 p.Article

Earlier detection of myocardial injury in a preliminary evaluation using a new troponin I assay with improved sensitivityMELANSON, Stacy E. F; MORROW, David A; JAROLIM, Petr et al.American journal of clinical pathology. 2007, Vol 128, Num 2, pp 282-286, issn 0002-9173, 5 p.Article

Prognostic Performance of Multiple Biomarkers in Patients With Non―ST-Segment Elevation Acute Coronary SyndromeO'MALLEY, Ryan G; BONACA, Marc P; SCIRICA, Benjamin M et al.Journal of the American College of Cardiology. 2014, Vol 63, Num 16, pp 1644-1653, issn 0735-1097, 10 p.Article

Coronary Stent Thrombosis With Vorapaxar Versus Placebo: Results From the TRA 2°P-TIMI 50 TrialBONACA, Marc P; SCIRICA, Benjamin M; BRAUNWALD, Eugene et al.Journal of the American College of Cardiology. 2014, Vol 64, Num 22, pp 2309-2317, issn 0735-1097, 9 p.Article

New Ischemic Stroke and Outcomes With Vorapaxar Versus Placebo: Results From the TRA 2°P-TIMI 50 TrialBONACA, Marc P; SCIRICA, Benjamin M; BRAUNWALD, Eugene et al.Journal of the American College of Cardiology. 2014, Vol 64, Num 22, pp 2318-2326, issn 0735-1097, 9 p.Article

Vorapaxar in the Secondary Prevention of Atherothrombotic EventsMORROW, David A; BRAUNWALD, Eugene; OUDE OPHUIS, A. J et al.The New England journal of medicine. 2012, Vol 366, Num 15, pp 1404-1413, issn 0028-4793, 10 p.Article

Biomarkers in Cardiovascular Clinical Trials: Past, Present, FutureHALIM, Sharif A; NEWBY, L. Kristin; OHMAN, E. Magnus et al.Clinical chemistry (Baltimore, Md.). 2012, Vol 58, Num 1, pp 45-53, issn 0009-9147, 9 p.Article

Genomewide Association Studies in Cardiovascular Disease—An Update 2011ZELLER, Tanja; BLANKENBERG, Stefan; DIEMERT, Patrick et al.Clinical chemistry (Baltimore, Md.). 2012, Vol 58, Num 1, pp 92-103, issn 0009-9147, 12 p.Article

Emerging Biomarkers in Heart FailureVAN KIMMENADE, Roland R. J; JANUZZI, James L.Clinical chemistry (Baltimore, Md.). 2012, Vol 58, Num 1, pp 127-138, issn 0009-9147, 12 p.Article

Absolute and Relative Kinetic Changes of High-Sensitivity Cardiac Troponin T in Acute Coronary Syndrome and in Patients with Increased Troponin in the Absence of Acute Coronary SyndromeMUELLER, Matthias; BIENER, Moritz; VAFAIE, Mehrshad et al.Clinical chemistry (Baltimore, Md.). 2012, Vol 58, Num 1, pp 209-218, issn 0009-9147, 10 p.Article

Troponin T Measurements by High-Sensitivity vs Conventional Assays for Risk Stratification in Acute DyspneaVAN WIJK, Sandra; JACOBS, Leo; VAN DIEIJEN-VISSER, Marja P et al.Clinical chemistry (Baltimore, Md.). 2012, Vol 58, Num 1, pp 284-292, issn 0009-9147, 9 p.Article

Prospective Evaluation of the Prognostic Implications of Improved Assay Performance With a Sensitive Assay for Cardiac Troponin I : Biomarkers in Cardiovascular DiseaseBONACA, Marc; SCIRICA, Benjamin; SABATINE, Marc et al.Journal of the American College of Cardiology. 2010, Vol 55, Num 19, pp 2118-2124, issn 0735-1097, 7 p.Article

Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: Design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic lschemic Events (TRA 2°P)-TIMI 50 trialMORROW, David A; SCIRICA, Benjamin M; FOX, Keith A. A et al.The American heart journal. 2009, Vol 158, Num 3, pp 335-341, issn 0002-8703, 7 p.Article

Evaluation of the Glycometabolic Effects of Ranolazine in Patients With and Without Diabetes Mellitus in the MERLIN-TIMI 36 Randomized Controlled TrialMORROW, David A; SCIRICA, Benjamin M; CHAITMAN, Bernard R et al.Circulation (New York, N.Y.). 2009, Vol 119, Num 15, pp 2032-2039, issn 0009-7322, 8 p.Article

Prognostic Utility of ApoB/AI, Total Cholesterol/HDL, Non-HDL Cholesterol, or hs-CRP as Predictors of Clinical Risk in Patients Receiving Statin Therapy After Acute Coronary Syndromes : Results From PROVE IT-TIMI 22RAY, Kausik K; CANNON, Christopher P; CAIRNS, Richard et al.Arteriosclerosis, thrombosis, and vascular biology. 2009, Vol 29, Num 3, pp 424-430, issn 1079-5642, 7 p.Article

Thrombolysis in Myocardial Infarction (TIMI) Risk Index predicts long-term mortality and heart failure in patients with ST-elevation myocardial infarction in the TIMI 2 clinical trialTRUONG, Quynh A; CANNON, Christopher P; ZAKAI, Nell A et al.The American heart journal. 2009, Vol 157, Num 4, pp 673-679, issn 0002-8703, 7 p.Article

Timing and Duration of Myocardial Ischemia on Holter Monitoring Following Percutaneous Coronary Intervention and Their Association With Clinical Outcomes (a PROTECT-TIMI 30 Substudy Analysis)GIBSON, C. Michael; PRIDE, Yuri B; BUROS, Jacqueline L et al.The American journal of cardiology. 2009, Vol 104, Num 1, pp 36-40, issn 0002-9149, 5 p.Article

Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome : myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18WEBER, Michael; HAMM, Christian; HAZEN, Stanley L et al.European heart journal. 2008, Vol 29, Num 9, issn 0195-668X, 1079-1081, 1096-1102 [10 p.]Article

Thrombus Precursor Protein and Clinical Outcomes in Patients With Acute Coronary Syndromes. CommentaryMEGA, Jessica L; MORROW, David A; DE LEMOS, James A et al.Journal of the American College of Cardiology. 2008, Vol 51, Num 25, pp 2422-2431, issn 0735-1097, 10 p.Article

A strategy of using enoxaparin as adjunctive antithrombin therapy reduces death and recurrent myocardial infarction in patients who achieve early st-segment resolution after fibrinolytic therapy : the ExTRACT-TIMI 25 ECG studySCIRICA, Benjamin M; MORROW, David A; BRAUNWALD, Eugene et al.European heart journal. 2007, Vol 28, Num 17, pp 2070-2076, issn 0195-668X, 7 p.Article

Clinical application of C-reactive protein across the spectrum of acute coronary syndromesSCIRICA, Benjamin M; MORROW, David A; CANNON, Christopher P et al.Clinical chemistry (Baltimore, Md.). 2007, Vol 53, Num 10, pp 1800-1807, issn 0009-9147, 8 p.Article

Effect of enoxaparin versus unfractionated heparin in diabetic patients with ST-elevation myocardial infarction in the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25) trialMORROW, David A; ANTMAN, Elliott M; MURPHY, Sabina A et al.The American heart journal. 2007, Vol 154, Num 6, pp 1078-1084, issn 0002-8703, 7 p.Article

A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents the PROTECT-TIMI-30 trial. CommentaryGIBSON, C. Michael; MORROW, David A; COHEN, David J et al.Journal of the American College of Cardiology. 2006, Vol 47, Num 12, pp 2364-2383, issn 0735-1097, 20 p.Article